BAG-1 expression in normal endometrium, endometrial hyperplasia and endometrial cancer

Jae Yun Song, Ji Won Kim, Jae Kwan Lee, Nak Woo Lee, Bom Woo Yeom, Sun Haeng Kim, Kyu Wan Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background. BAG-1 (Bcl-2-associated athanogene 1) is a BCL-2 binding anti-apoptotic protein that may play a role in carcinogenesis. The purpose of this study is to compare the expression rate of BAG-1 in normal endometrium, endometrial hyperplasia and endometrial cancer, and further to determine a correlation between BAG-1 expression and clinicopathological parameters, and overall survival. Methods. Tissue samples from 43 patients who were diagnosed with endometrial cancer, tissue samples from 20 patients with endometrial hyperplasia and tissue samples from 20 normal patients were included in the study. Immunohistochemical analyses were performed using a polyclonal anti-BAG-1 antibody from paraffin-embedded blocks. Results. Cytoplasmic BAG-1 expression of the normal endometrium, endometrial hyperplasia and endometrial cancer samples was 4/20 (20%), 3/20 (15%) and 27/43 (62%), respectively. Nuclear BAG-1 expression was 17/20 (85%), 12/20 (60%) and 16/43 (37%), respectively. Cytoplasmic BAG-1 expression correlated with cancer grade (p=0.02). The mean survival of patients with positive/negative cytoplasmic BAG-1 expression and nuclear BAG-1 expression was 49.4/45.4 and 54.0/41.1 months, respectively, but there was no statistical difference for survival (log-rank p=0.31, p=0.55). Conclusion. Cytoplasmic BAG-1 is more frequently expressed in endometrial cancer tissues than in normal and endometrial hyperplasia tissues (p=0.0007), and its expression correlates with cancer grade. Nuclear BAG-1 is more frequently expressed in the normal endometrium and hyperplasia tissues than in endometrial cancer tissues (p=0.002). Neither cytoplasmic nor nuclear BAG-1 expression is associated with survival.

Original languageEnglish
Pages (from-to)862-867
Number of pages6
JournalActa Obstetricia et Gynecologica Scandinavica
Volume87
Issue number8
DOIs
Publication statusPublished - 2008 Aug 22

Fingerprint

Endometrial Hyperplasia
Endometrial Neoplasms
Endometrium
Survival
Apoptosis Regulatory Proteins
Paraffin
Hyperplasia
Neoplasms
Carrier Proteins
Carcinogenesis
Antibodies

Keywords

  • BAG-1
  • BCL-2
  • Endometrial cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

BAG-1 expression in normal endometrium, endometrial hyperplasia and endometrial cancer. / Song, Jae Yun; Kim, Ji Won; Lee, Jae Kwan; Lee, Nak Woo; Yeom, Bom Woo; Kim, Sun Haeng; Lee, Kyu Wan.

In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 87, No. 8, 22.08.2008, p. 862-867.

Research output: Contribution to journalArticle

@article{d64598f4286b4cb4b81a48a487908d72,
title = "BAG-1 expression in normal endometrium, endometrial hyperplasia and endometrial cancer",
abstract = "Background. BAG-1 (Bcl-2-associated athanogene 1) is a BCL-2 binding anti-apoptotic protein that may play a role in carcinogenesis. The purpose of this study is to compare the expression rate of BAG-1 in normal endometrium, endometrial hyperplasia and endometrial cancer, and further to determine a correlation between BAG-1 expression and clinicopathological parameters, and overall survival. Methods. Tissue samples from 43 patients who were diagnosed with endometrial cancer, tissue samples from 20 patients with endometrial hyperplasia and tissue samples from 20 normal patients were included in the study. Immunohistochemical analyses were performed using a polyclonal anti-BAG-1 antibody from paraffin-embedded blocks. Results. Cytoplasmic BAG-1 expression of the normal endometrium, endometrial hyperplasia and endometrial cancer samples was 4/20 (20{\%}), 3/20 (15{\%}) and 27/43 (62{\%}), respectively. Nuclear BAG-1 expression was 17/20 (85{\%}), 12/20 (60{\%}) and 16/43 (37{\%}), respectively. Cytoplasmic BAG-1 expression correlated with cancer grade (p=0.02). The mean survival of patients with positive/negative cytoplasmic BAG-1 expression and nuclear BAG-1 expression was 49.4/45.4 and 54.0/41.1 months, respectively, but there was no statistical difference for survival (log-rank p=0.31, p=0.55). Conclusion. Cytoplasmic BAG-1 is more frequently expressed in endometrial cancer tissues than in normal and endometrial hyperplasia tissues (p=0.0007), and its expression correlates with cancer grade. Nuclear BAG-1 is more frequently expressed in the normal endometrium and hyperplasia tissues than in endometrial cancer tissues (p=0.002). Neither cytoplasmic nor nuclear BAG-1 expression is associated with survival.",
keywords = "BAG-1, BCL-2, Endometrial cancer",
author = "Song, {Jae Yun} and Kim, {Ji Won} and Lee, {Jae Kwan} and Lee, {Nak Woo} and Yeom, {Bom Woo} and Kim, {Sun Haeng} and Lee, {Kyu Wan}",
year = "2008",
month = "8",
day = "22",
doi = "10.1080/00016340802087884",
language = "English",
volume = "87",
pages = "862--867",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - BAG-1 expression in normal endometrium, endometrial hyperplasia and endometrial cancer

AU - Song, Jae Yun

AU - Kim, Ji Won

AU - Lee, Jae Kwan

AU - Lee, Nak Woo

AU - Yeom, Bom Woo

AU - Kim, Sun Haeng

AU - Lee, Kyu Wan

PY - 2008/8/22

Y1 - 2008/8/22

N2 - Background. BAG-1 (Bcl-2-associated athanogene 1) is a BCL-2 binding anti-apoptotic protein that may play a role in carcinogenesis. The purpose of this study is to compare the expression rate of BAG-1 in normal endometrium, endometrial hyperplasia and endometrial cancer, and further to determine a correlation between BAG-1 expression and clinicopathological parameters, and overall survival. Methods. Tissue samples from 43 patients who were diagnosed with endometrial cancer, tissue samples from 20 patients with endometrial hyperplasia and tissue samples from 20 normal patients were included in the study. Immunohistochemical analyses were performed using a polyclonal anti-BAG-1 antibody from paraffin-embedded blocks. Results. Cytoplasmic BAG-1 expression of the normal endometrium, endometrial hyperplasia and endometrial cancer samples was 4/20 (20%), 3/20 (15%) and 27/43 (62%), respectively. Nuclear BAG-1 expression was 17/20 (85%), 12/20 (60%) and 16/43 (37%), respectively. Cytoplasmic BAG-1 expression correlated with cancer grade (p=0.02). The mean survival of patients with positive/negative cytoplasmic BAG-1 expression and nuclear BAG-1 expression was 49.4/45.4 and 54.0/41.1 months, respectively, but there was no statistical difference for survival (log-rank p=0.31, p=0.55). Conclusion. Cytoplasmic BAG-1 is more frequently expressed in endometrial cancer tissues than in normal and endometrial hyperplasia tissues (p=0.0007), and its expression correlates with cancer grade. Nuclear BAG-1 is more frequently expressed in the normal endometrium and hyperplasia tissues than in endometrial cancer tissues (p=0.002). Neither cytoplasmic nor nuclear BAG-1 expression is associated with survival.

AB - Background. BAG-1 (Bcl-2-associated athanogene 1) is a BCL-2 binding anti-apoptotic protein that may play a role in carcinogenesis. The purpose of this study is to compare the expression rate of BAG-1 in normal endometrium, endometrial hyperplasia and endometrial cancer, and further to determine a correlation between BAG-1 expression and clinicopathological parameters, and overall survival. Methods. Tissue samples from 43 patients who were diagnosed with endometrial cancer, tissue samples from 20 patients with endometrial hyperplasia and tissue samples from 20 normal patients were included in the study. Immunohistochemical analyses were performed using a polyclonal anti-BAG-1 antibody from paraffin-embedded blocks. Results. Cytoplasmic BAG-1 expression of the normal endometrium, endometrial hyperplasia and endometrial cancer samples was 4/20 (20%), 3/20 (15%) and 27/43 (62%), respectively. Nuclear BAG-1 expression was 17/20 (85%), 12/20 (60%) and 16/43 (37%), respectively. Cytoplasmic BAG-1 expression correlated with cancer grade (p=0.02). The mean survival of patients with positive/negative cytoplasmic BAG-1 expression and nuclear BAG-1 expression was 49.4/45.4 and 54.0/41.1 months, respectively, but there was no statistical difference for survival (log-rank p=0.31, p=0.55). Conclusion. Cytoplasmic BAG-1 is more frequently expressed in endometrial cancer tissues than in normal and endometrial hyperplasia tissues (p=0.0007), and its expression correlates with cancer grade. Nuclear BAG-1 is more frequently expressed in the normal endometrium and hyperplasia tissues than in endometrial cancer tissues (p=0.002). Neither cytoplasmic nor nuclear BAG-1 expression is associated with survival.

KW - BAG-1

KW - BCL-2

KW - Endometrial cancer

UR - http://www.scopus.com/inward/record.url?scp=49649083844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649083844&partnerID=8YFLogxK

U2 - 10.1080/00016340802087884

DO - 10.1080/00016340802087884

M3 - Article

VL - 87

SP - 862

EP - 867

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 8

ER -